KALA BIO, Inc.

Good morning and welcome to Kala Pharmaceuticals' first quarter 2021 financial results conference call. At this time, all participants are in listen-only mode. Following management prepared remarks, a Q&A session will be held as a reminder. This call is being recorded. I would now like to turn the call over to Nairanjan Kamraswanan, Senior Vice President of Strategy for Kala Pharmaceuticals. Please proceed.

Thank you, Operator, and thank you all for participating in today's call. Mark Iwiki, Chairman, President, and Chief Executive Officer, Todd Bazemore, Chief Operating Officer, Mary Remeth, Chief Financial Officer, and Kim Brazel, our Chief Medical Officer. Today's call is being webcast live. The webcast link can be found in the Investors and Media section of our website at www.calarx.com. During this call, we will be referring to non-GAAP financial measures which are not prepared in accordance with generally accepted accounting principles. Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available in our press release issued today, which can also be found on our website. On this call, we will make certain comments about CALA's future expectations, plans, and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements will include statements regarding the potential market and commercial launch plans for ISUVIS, observations associated with our commercialization of ISUVIS and INVELTIS, and the sufficiency of our cash resources. These and other forward-looking statements are based on the beliefs and expectations of management as of this conference call. Our actual results may differ materially from our expectations. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances that occur after this conference call, except as required by law. Investors should carefully read the risks and uncertainties described in today's press release, as well as the risk factors, which identify specific factors that may cause actual results or events to differ materially from those described in our forward-looking statements included in the company's quarterly report on Form 10-Q and other filings we make with the SEC. The Form 10-Q will be filed with the SEC later today and will be available on our website. I will now turn the call over to Kala CEO, Mark Iricchi.

Thanks, Niranjan, and good morning, everyone. Thank you for joining us today to review Kala's first quarter 2021 financial results and recent business highlights. It's an exciting time at Kala. We now have two commercial products available for eye care professionals and patients, Deep Relationships Across Health. the ophthalmology and optometry markets, and are advancing a suite of innovative NCE pipeline programs. Taken together, we are working to extend our reach to address a broad range of front and back-of-the-eye diseases and help millions more patients. We believe this provides us with a tremendous foundation for future growth. As we look to the remainder of 2021, we are working hard to ensure the commercial success of ISUVIS and in VELTUS. We are pleased with the early ISUVIS launch feedback from doctors and patients as well as the significant commercial coverage that we've been able to secure in the few months since launch. In addition, we are encouraged by recent trends suggesting that elective ocular surgeries are growing toward pre-COVID levels as vaccines are becoming more readily available. We believe this positions in VELTUS for future growth in the market. We also continue to advance our next wave of therapeutic candidates, which includes programs for the treatment of both front and back of the eye diseases. As we have described before, we believe these programs, which include a selective glucocorticoid receptor modulator, or SEGRM, and a tyrosine kinase inhibitor, or TKI, have the potential to fuel future growth for Kala by leveraging our existing capabilities and extensive scientific know-how to deliver new solutions for retinal disorders that affect millions of people worldwide. We look forward to providing additional detail around these programs later this year as they move toward clinical development. We believe we're in a strong position to advance our portfolio of innovative products and development programs. This morning, we announced we entered into a new credit facility and increased the funds available to us subject to certain conditions to up to $125 million and also pushed out the beginning of our debt repayment obligations by a minimum of two years. This is an important milestone that ultimately contributes to enhancing our cash runway. We now anticipate that our cash resources as of March 31st, 2021, together with anticipated revenue from ISUVIS and INVELTIS, will enable us to fund our operations for at least two years as we continue to invest in our company. Mary will provide some additional comments about this update later in the call. I will now turn the call over to Todd to review our commercial progress with ISUVIS and INVELTIS.